Deerfield Management NVST Position
ActiveDeerfield Management trimmed their position in Envista Holdings Corp (NVST) in Q4 2025, holding $49.5M worth of shares across 2,280,498 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
About Envista Holdings Corp
Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
Full company profile →Short Interest
6.7%
4.0 days to cover
Deerfield Management NVST Position History
Frequently Asked Questions
Does Deerfield Management own NVST?
Yes. As of Q4 2025, Deerfield Management holds 2,280,498 shares of Envista Holdings Corp (NVST) valued at $49.5M. This data comes from their SEC 13F filing.
How many hedge funds own NVST?
1 specialist biotech hedge fund currently holds NVST. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy NVST?
Deerfield Management's position in NVST was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's NVST position increasing or decreasing?
Deerfield Management trimmed their NVST position in the most recent quarter, reducing by 13,538 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NVSTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →